1. Use of regional citrate anticoagulation for continuous venovenous hemodialysis in critically ill cancer patients with acute kidney injury
- Author
-
Renato Antunes Caires, Cilene Muniz Soares, Verônica Torres da Costa e Silva, Fernanda Oliveira Coelho, Elerson C. Costalonga, Juliana Silva Bezerra, Luciane Oikawa, Ludhmila Abrahão Hajjar, Julia Tizue Fukushima, Ana Paula Leandro Oliveira, and Emmanuel A. Burdmann
- Subjects
Male ,Critical Care ,Critical Illness ,030232 urology & nephrology ,Disease ,Critical Care and Intensive Care Medicine ,Citric Acid ,law.invention ,Sepsis ,Electrolytes ,03 medical and health sciences ,Patient Admission ,0302 clinical medicine ,Renal Dialysis ,law ,Neoplasms ,CITRINO ,Humans ,Pain Management ,Medicine ,Thrombolytic Therapy ,Prospective Studies ,Aged ,Calcium metabolism ,Hypocalcemia ,Nutritional Support ,Platelet Count ,Genitourinary system ,business.industry ,Continuous venovenous hemodialysis ,Acute kidney injury ,Anticoagulants ,Cancer ,030208 emergency & critical care medicine ,Acute Kidney Injury ,Middle Aged ,medicine.disease ,Intensive care unit ,Anesthesia ,Calcium ,Female ,business - Abstract
This study aimed to evaluate the safety and efficacy of a regional citrate anticoagulation (RCA) protocol for continuous venovenous hemodialysis (CVVHD) in cancer patients with acute kidney injury (AKI) in the intensive care unit (ICU) setting.One hundred twenty two consecutive ICU cancer patients with AKI treated with citrate-based CVVHD were prospectively evaluated in this prospective observational study.A total of 7198 h of CVVHD therapy (250 filters) were performed. Patients were 61.3 ± 15.7 years old, 78% had solid cancer and the main AKI cause was sepsis (50%). The in-hospital mortality was 78.7%. Systemic ionized calcium (SCai) was 4.35 (4.10-4.60) mg/dL, severe hypocalcemia (SCai3.6 mg/dL) was observed in 4.3% of procedures and post-filter ionized calcium was 1.60 (1.40-1.80) mg/dL. Median filter patency was 24.8 (11-43) hours. Factors related to filter clotting were: no tumor evidence (OR 0.44, CI 0.18-0.99); genitourinary tumor (OR 1.83, CI 1.18-2.81); platelets number (each 10,000/mmFilter patency was relatively short and clotting was associated with active cancer disease, genitourinary tumor, lower citrate dose and lower INR.
- Published
- 2018
- Full Text
- View/download PDF